Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma

Stefan Fritz, Carlos Fernandez-Del Castillo, Mari Mino-Kenudson, Stefano Crippa, Vikram Deshpande, Gregory Y. Lauwers, Andrew L. Warshaw, Sarah P. Thayer, A. John Iafrate

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

OBJECTIVE: To determine whether intraductal papillary mucinous neoplasms of the pancreas (IPMNs) have a different genetic background compared with ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: The biologic and clinical behavior of IPMNs and IPMN-associated adenocarcinomas is different from PDAC in having a less aggressive tumor growth and significantly improved survival. Up to date, the molecular mechanisms underlying the clinical behavior of IPMNs are incompletely understood. METHODS: 128 cystic pancreatic lesions were prospectively identified during the course of 2 years. From the corresponding surgical specimens, 57 IPMNs were separated and subdivided by histologic criteria into those with low-grade dysplasia, moderate dysplasia, high-grade dysplasia, and invasive cancer. Twenty specimens were suitable for DNA isolation and subsequent performance of array CGH. RESULTS: While none of the IPMNs with low-grade dysplasia displayed detectable chromosomal aberrations, IPMNs with moderate and high-grade dysplasia showed frequent copy number alterations. Commonly lost regions were located on chromosome 5q, 6q, 10q, 11q, 13q, 18q, and 22q. The incidence of loss of chromosome 5q, 6q, and 11q was significantly higher in IPMNs with high-grade dysplasia or invasion compared with PDAC. Ten of 13 IPMNs with moderate dysplasia or malignancy had loss of part or all of chromosome 6q, with a minimal deleted region between linear positions 78.0 and 130.0. CONCLUSIONS: This study is the first to use array CGH to characterize IPMNs. Recurrent cytogenetic alterations were identified and were different than those described in PDAC. Array CGH may help distinguish between these 2 entities and give insight into the differences in their biology and prognosis.

Original languageEnglish (US)
Pages (from-to)440-447
Number of pages8
JournalAnnals of surgery
Volume249
Issue number3
DOIs
StatePublished - Mar 1 2009

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Chromosomes
Neoplasms
Cytogenetics
Chromosome Aberrations
DNA
Incidence
Growth

Keywords

  • Chromosomal aberrations
  • Comparative genomic hybridization
  • Genetic characterization
  • Intraductal papillary mucinous neoplasms
  • KRAS

ASJC Scopus subject areas

  • Surgery

Cite this

Fritz, S., Fernandez-Del Castillo, C., Mino-Kenudson, M., Crippa, S., Deshpande, V., Lauwers, G. Y., ... Iafrate, A. J. (2009). Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma. Annals of surgery, 249(3), 440-447. https://doi.org/10.1097/SLA.0b013e31819a6e16

Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma. / Fritz, Stefan; Fernandez-Del Castillo, Carlos; Mino-Kenudson, Mari; Crippa, Stefano; Deshpande, Vikram; Lauwers, Gregory Y.; Warshaw, Andrew L.; Thayer, Sarah P.; Iafrate, A. John.

In: Annals of surgery, Vol. 249, No. 3, 01.03.2009, p. 440-447.

Research output: Contribution to journalArticle

Fritz, S, Fernandez-Del Castillo, C, Mino-Kenudson, M, Crippa, S, Deshpande, V, Lauwers, GY, Warshaw, AL, Thayer, SP & Iafrate, AJ 2009, 'Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma', Annals of surgery, vol. 249, no. 3, pp. 440-447. https://doi.org/10.1097/SLA.0b013e31819a6e16
Fritz, Stefan ; Fernandez-Del Castillo, Carlos ; Mino-Kenudson, Mari ; Crippa, Stefano ; Deshpande, Vikram ; Lauwers, Gregory Y. ; Warshaw, Andrew L. ; Thayer, Sarah P. ; Iafrate, A. John. / Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma. In: Annals of surgery. 2009 ; Vol. 249, No. 3. pp. 440-447.
@article{fce383f74a484ccda63b0b057cefe546,
title = "Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma",
abstract = "OBJECTIVE: To determine whether intraductal papillary mucinous neoplasms of the pancreas (IPMNs) have a different genetic background compared with ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: The biologic and clinical behavior of IPMNs and IPMN-associated adenocarcinomas is different from PDAC in having a less aggressive tumor growth and significantly improved survival. Up to date, the molecular mechanisms underlying the clinical behavior of IPMNs are incompletely understood. METHODS: 128 cystic pancreatic lesions were prospectively identified during the course of 2 years. From the corresponding surgical specimens, 57 IPMNs were separated and subdivided by histologic criteria into those with low-grade dysplasia, moderate dysplasia, high-grade dysplasia, and invasive cancer. Twenty specimens were suitable for DNA isolation and subsequent performance of array CGH. RESULTS: While none of the IPMNs with low-grade dysplasia displayed detectable chromosomal aberrations, IPMNs with moderate and high-grade dysplasia showed frequent copy number alterations. Commonly lost regions were located on chromosome 5q, 6q, 10q, 11q, 13q, 18q, and 22q. The incidence of loss of chromosome 5q, 6q, and 11q was significantly higher in IPMNs with high-grade dysplasia or invasion compared with PDAC. Ten of 13 IPMNs with moderate dysplasia or malignancy had loss of part or all of chromosome 6q, with a minimal deleted region between linear positions 78.0 and 130.0. CONCLUSIONS: This study is the first to use array CGH to characterize IPMNs. Recurrent cytogenetic alterations were identified and were different than those described in PDAC. Array CGH may help distinguish between these 2 entities and give insight into the differences in their biology and prognosis.",
keywords = "Chromosomal aberrations, Comparative genomic hybridization, Genetic characterization, Intraductal papillary mucinous neoplasms, KRAS",
author = "Stefan Fritz and {Fernandez-Del Castillo}, Carlos and Mari Mino-Kenudson and Stefano Crippa and Vikram Deshpande and Lauwers, {Gregory Y.} and Warshaw, {Andrew L.} and Thayer, {Sarah P.} and Iafrate, {A. John}",
year = "2009",
month = "3",
day = "1",
doi = "10.1097/SLA.0b013e31819a6e16",
language = "English (US)",
volume = "249",
pages = "440--447",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma

AU - Fritz, Stefan

AU - Fernandez-Del Castillo, Carlos

AU - Mino-Kenudson, Mari

AU - Crippa, Stefano

AU - Deshpande, Vikram

AU - Lauwers, Gregory Y.

AU - Warshaw, Andrew L.

AU - Thayer, Sarah P.

AU - Iafrate, A. John

PY - 2009/3/1

Y1 - 2009/3/1

N2 - OBJECTIVE: To determine whether intraductal papillary mucinous neoplasms of the pancreas (IPMNs) have a different genetic background compared with ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: The biologic and clinical behavior of IPMNs and IPMN-associated adenocarcinomas is different from PDAC in having a less aggressive tumor growth and significantly improved survival. Up to date, the molecular mechanisms underlying the clinical behavior of IPMNs are incompletely understood. METHODS: 128 cystic pancreatic lesions were prospectively identified during the course of 2 years. From the corresponding surgical specimens, 57 IPMNs were separated and subdivided by histologic criteria into those with low-grade dysplasia, moderate dysplasia, high-grade dysplasia, and invasive cancer. Twenty specimens were suitable for DNA isolation and subsequent performance of array CGH. RESULTS: While none of the IPMNs with low-grade dysplasia displayed detectable chromosomal aberrations, IPMNs with moderate and high-grade dysplasia showed frequent copy number alterations. Commonly lost regions were located on chromosome 5q, 6q, 10q, 11q, 13q, 18q, and 22q. The incidence of loss of chromosome 5q, 6q, and 11q was significantly higher in IPMNs with high-grade dysplasia or invasion compared with PDAC. Ten of 13 IPMNs with moderate dysplasia or malignancy had loss of part or all of chromosome 6q, with a minimal deleted region between linear positions 78.0 and 130.0. CONCLUSIONS: This study is the first to use array CGH to characterize IPMNs. Recurrent cytogenetic alterations were identified and were different than those described in PDAC. Array CGH may help distinguish between these 2 entities and give insight into the differences in their biology and prognosis.

AB - OBJECTIVE: To determine whether intraductal papillary mucinous neoplasms of the pancreas (IPMNs) have a different genetic background compared with ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: The biologic and clinical behavior of IPMNs and IPMN-associated adenocarcinomas is different from PDAC in having a less aggressive tumor growth and significantly improved survival. Up to date, the molecular mechanisms underlying the clinical behavior of IPMNs are incompletely understood. METHODS: 128 cystic pancreatic lesions were prospectively identified during the course of 2 years. From the corresponding surgical specimens, 57 IPMNs were separated and subdivided by histologic criteria into those with low-grade dysplasia, moderate dysplasia, high-grade dysplasia, and invasive cancer. Twenty specimens were suitable for DNA isolation and subsequent performance of array CGH. RESULTS: While none of the IPMNs with low-grade dysplasia displayed detectable chromosomal aberrations, IPMNs with moderate and high-grade dysplasia showed frequent copy number alterations. Commonly lost regions were located on chromosome 5q, 6q, 10q, 11q, 13q, 18q, and 22q. The incidence of loss of chromosome 5q, 6q, and 11q was significantly higher in IPMNs with high-grade dysplasia or invasion compared with PDAC. Ten of 13 IPMNs with moderate dysplasia or malignancy had loss of part or all of chromosome 6q, with a minimal deleted region between linear positions 78.0 and 130.0. CONCLUSIONS: This study is the first to use array CGH to characterize IPMNs. Recurrent cytogenetic alterations were identified and were different than those described in PDAC. Array CGH may help distinguish between these 2 entities and give insight into the differences in their biology and prognosis.

KW - Chromosomal aberrations

KW - Comparative genomic hybridization

KW - Genetic characterization

KW - Intraductal papillary mucinous neoplasms

KW - KRAS

UR - http://www.scopus.com/inward/record.url?scp=63449085593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449085593&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e31819a6e16

DO - 10.1097/SLA.0b013e31819a6e16

M3 - Article

C2 - 19247032

AN - SCOPUS:63449085593

VL - 249

SP - 440

EP - 447

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -